Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

BACKGROUND: Modern guidelines recommend sodium-glucose cotransporter-2 (SGLT2) inhibitors as the preferred antihyperglycemic agents for patients with type 2 diabetes and chronic kidney disease. However, the mechanisms underlying the renal protective effect of SGLT2 inhibitors are not fully understoo...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimontov, Vadim V, Korbut, Anton I, Taskaeva, Iuliia S, Bgatova, Nataliya P, Dashkin, Maksim V, Orlov, Nikolai B, Khotskina, Anna S, Zavyalov, Evgenii L, Klein, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754166/
https://www.ncbi.nlm.nih.gov/pubmed/33384767
http://dx.doi.org/10.4239/wjd.v11.i12.596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754166/
https://www.ncbi.nlm.nih.gov/pubmed/33384767
http://dx.doi.org/10.4239/wjd.v11.i12.596

Ejemplares similares